Detalhe da pesquisa
1.
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
N Engl J Med
; 388(22): 2058-2070, 2023 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37256976
2.
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer.
Br J Cancer
; 130(8): 1377-1387, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38396173
3.
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
Lancet Oncol
; 23(7): 851-864, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35671774
4.
Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer.
JCO Precis Oncol
; 8: e2300456, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38691816
5.
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
NPJ Breast Cancer
; 9(1): 64, 2023 Aug 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37543694
6.
Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.
Sci Rep
; 12(1): 2699, 2022 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35177674
7.
Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
J Clin Oncol
; 40(22): 2408-2419, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35658506
8.
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kß/δ, in Patients with Advanced Solid Tumors.
Clin Cancer Res
; 28(11): 2257-2269, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35247924
9.
Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers.
Nat Commun
; 12(1): 1780, 2021 03 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33741979
10.
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.
NPJ Breast Cancer
; 7(1): 44, 2021 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33863913
11.
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.
J Clin Oncol
; 38(5): 423-433, 2020 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31841354
12.
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.
Clin Cancer Res
; 26(14): 3720-3731, 2020 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32220884
13.
Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT).
Clin Cancer Res
; 26(7): 1574-1585, 2020 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31836609
14.
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer.
Clin Cancer Res
; 26(15): 3947-3957, 2020 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32312891
15.
Epithelial human leukocyte antigen-DR expression predicts reduced recurrence rates and prolonged survival in rectal cancer patients.
Clin Cancer Res
; 14(4): 1073-9, 2008 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18281539
16.
Caspase-3 activity predicts local recurrence in rectal cancer.
Clin Cancer Res
; 13(19): 5810-5, 2007 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17908973
17.
Cyclooxygenase 2 expression in rectal cancer is of prognostic significance in patients receiving preoperative radiotherapy.
Clin Cancer Res
; 13(10): 2955-60, 2007 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17504996
18.
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
NPJ Breast Cancer
; 9(1): 76, 2023 Sep 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37726304
19.
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers.
Clin Cancer Res
; 24(9): 2050-2059, 2018 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29066505
20.
Prognostic value of apoptosis in rectal cancer patients of the dutch total mesorectal excision trial: radiotherapy is redundant in intrinsically high-apoptotic tumors.
Clin Cancer Res
; 12(21): 6432-6, 2006 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17085656